VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds. The private placement involves 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants, priced at a combined $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, with an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company agreed to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, subject to customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction. For more details, visit https://ibn.fm/7Ov0B.
This capital raise is significant for VivoSim as it provides financial resources to advance its focus on pharmaceutical and biotechnology services. The company specializes in testing drugs and drug candidates using three-dimensional (3D) human tissue models of liver and intestine. VivoSim offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA, and more information is available at https://vivosim.ai/.
The implications of this announcement are twofold. First, the participation of a healthcare-focused institutional investor underscores confidence in VivoSim's technology and business model. Second, the amendment of existing warrants at a lower exercise price may incentivize warrant holders to convert, potentially strengthening the company's balance sheet. This funding positions VivoSim to continue its research and development efforts, particularly as regulatory trends move toward reducing animal testing. The private placement avoids dilutive public offering costs and provides a streamlined capital infusion. Overall, this development highlights the growing interest in innovative drug testing methodologies that align with FDA initiatives.
